Nivolumab / Brentuximab Vedotin (Checkmate 744)

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)

Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)

Recruiting

Summary

The aim of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine) is safe and effective in treating patients with Hodgkin's lymphoma (cHL).

Main inclusion criteria

  • Classic Hodgkin Lymphoma (cHL), relapsed or refractory
  • Children, adolescnes and young adults ( 5 - 30 years))

Sponsor

Bristol-Myers Squibb

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen